NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

Smitty, I'll agree with most of what you're saying about AVXL including a $100 valuation post European approval. I believe you're selling NWBO short, not because the British market in GBM is so big, but rather because the worldwide demand in solid cancers is enormous, and that's where we're headed.

From where we are today, remember, $2.50 for us is like $100 for AVXL, a ten banger. I believe our potential of going to $25 is far greater than AVXL's of going to $1000, that's a hundred banger.

Don't get me wrong, in time AVXL could very possibly get there, but I believe that just GBM could do $25 or much more for NWBO once we have multiple approvals, and frankly it will be used off label against other cancers until it gains label expansion.

I like both companies, or I wouldn't be invested. LP has had a much tougher time reaching this point, but we've potentially on the verge of tremendous success. I do expect AVXL to get European approval sometime this year, the question is, will it take just the 210 days we originally thought for DCVax-L, or will it be closer to our experience with the UK, over a year.

Gary